Rates ofERBB2Alterations across Melanoma Subtypes and a Complete Response to Trastuzumab Emtansine in anERBB2-Amplified Acral Melanoma
- 1 December 2018
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 24 (23) , 5815-5819
Abstract
Purpose: Patients with BRAF V600 wild-type melanoma whose tumors progress on checkpoint inhibition currently have limited therapeutic options, and additional rational treatment targets are needed. ERBB2 alterations may be amenable to targeted inhibition, but the rate of ERBB2 alterations across melanoma subtypes is not well described. Patients and Methods: All patients with nonuveal melanoma (cutaneous, acral, mucosal, and unknown primary) whose tumors underwent multigene sequencing with MSK-IMPACT at Memorial Sloan Kettering Cancer Center (New York, NY) from 2014 to 2018 were reviewed for known or likely oncogenic somatic alterations in ERBB2 and the other known canonical driver genes BRAF, NRAS, KIT, NF1, GNAQ, and GNA11. Results: A patient with acral melanoma resistant to checkpoint inhibition was found to have ERBB2 amplification and achieved a durable complete response to trastuzumab emtansine. Tumor sequencing results from 732 melanoma cases were analyzed for ERBB2 and canonical driver gene alterations. ERBB2 amplifications were detected in acral (3%) and mucosal (3%) melanomas. ERBB2 mutations were found in cutaneous (1%), acral (2%), and mucosal (2%) subtypes and frequently cooccurred with NF1 alterations. Among the 140 patients whose tumors lacked canonical driver alterations, ERBB2 amplifications were detected in acral (7%) and mucosal (6%) melanomas. Conclusions: ERBB2 amplification is present in a minority of acral lentiginous and mucosal melanomas. Activating mutations in ERBB2 were identified in nonuveal melanoma subtypes and are frequently comutated with canonical drivers. HER2 could represent a therapeutically relevant target across melanoma subtypes.Keywords
Funding Information
- MSKCC (P30 CA008748)
This publication has 23 references indexed in Scilit:
- Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)The Journal of Molecular Diagnostics, 2015
- HER2-directed therapy: current treatment options for HER2-positive breast cancerBreast Cancer, 2015
- Trastuzumab emtansine: mechanisms of action and drug resistanceBreast Cancer Research, 2014
- The Molecular Pathology of Melanoma: An Integrated Taxonomy of Melanocytic NeoplasiaAnnual Review of Pathology: Mechanisms of Disease, 2014
- Activating HER2 Mutations in HER2 Gene Amplification Negative Breast CancerCancer Discovery, 2013
- Trastuzumab Emtansine for HER2-Positive Advanced Breast CancerNew England Journal of Medicine, 2012
- KIT as a Therapeutic Target in Metastatic MelanomaJAMA, 2011
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Distinct Sets of Genetic Alterations in MelanomaNew England Journal of Medicine, 2005
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005